Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.

Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients

Abstract

Objective

It has been indicated that there is a tight association between cancer and different factors, such as environment and genetics, including aberrantly expressed microRNAs. The crucial role of microRNAs in the regulation of diverse signaling pathways in gastrointestinal cancer has been established in several studies. In this study, we aimed to evaluate the expression of microRNA-9 and -192 in colon and gastric cancers. After extracting the RNA from tissues and serum samples of patients, suffering from colon and gastric cancer, cDNA was synthesized. Then by performing quantitative real-time PCR, we evaluated the expression level of miR-9-5p and miR-192-5p in collected samples.

Results

Unlike to colon cancer in which the expression level of miR-9-5p remained unchanged, the relative expression of this miRNA decreased remarkably in gastric cancer (with P value < 0.05), in comparison with normal adjacent tissues. In agreement with this finding, we also found that the expression level of miR-192-5p was decreased in gastric cancer tissues, compared to normal gastric tissue. Given the reduction in the expression level of miR-9-5p and miR-192-5p in gastric cancer, it could be postulated to consider these miRNAs as promising diagnostic biomarkers.

Introduction

The critical role of environmental factors, including pollution, radiation, high fat in diet and infectious diseases, in the development and the progression of the human cancer is well-established in numerous studies, however, the significant effect of genetic factors on the initiation of different malignancies should not be underestimated [1,2,3,4,5,6]. Once the discovery of microRNAs, a small noncoding RNAs that act as endogenous silencers of numerous target genes [7], their remarkable role in the regulation of wide range of signaling pathways has been identified [8]. Although some microRNAs serve as oncogenes and activate cancer-related signaling pathways, the others could participate as tumor suppressors, affecting the expression of various biomolecules, such as neuropilin‑1, metalloproteinase 14 (MMP-14), Snail and so forth that are important for the formation of the malignancies [9,10,11,12]. Moreover, the unique profile of microRNA expression in human cancer cells and their tissue-specific manner made these small RNAs a potent biomolecules for both cancer diagnosis and screening [13]. The importance of miRNAs in the current cancer studies is not only restricted to cancer screening and lately intense interest has been devoted into miRNAs targeting as a novel strategies in cancer treatment [14].

In the longitude list of microRNAs, the expression level of both miR-9-5p and miR-192-5p has been shown to have an association with cancers. It has been indicated that miR-9 could regulate the expression of E-cadherin, a prominent molecule responsible for cell adhesion, in breast cancer cells [15, 16]. Moreover, another study showed that the over-expression of miR-192 in liver cancer cells not only increased the expression level of E-cadherin, but also modulated the angiogenesis process [17]. Garofalo et al. proposed that microRNAs participate in the pathogenesis of gastrointestinal cancer through regulating fundamental biological processes, such as proliferation and apoptosis [18]. Among different gastrointestinal cancers, gastric and colon cancer are the most prevalent ones by accounting for the 9% and 10% of invasive cancer, respectively [19]. In a study conducted by Bandres et al. it has been indicated that down-regulation of miR-451 was associated with worse prognosis in both gastric and colorectal cancer [20]. In another study, it has been proposed that while the expression level of miR-17-3p and miR-92 was raised in the patients with colorectal cancer, the plasma levels of these microRNAs significantly declined after surgery; introducing aforementioned microRNAs as a minimally-invasive molecular markers for colorectal screening [21]. Although multiple lines of evidence emphasized the significant role of miRNAs in different kind of cancers, as far as we are aware, the relationship between the expression of miR-9-5p, miR-192-5p (mature miRNA) and gastrointestinal cancer remains open to debate. In this study, we aimed to evaluate the expression of aforementioned miRNAs in samples collected from colon and gastric cancer patients.

Main text

Ethical statement

Approval to conduct this study was obtained from the Shahid Beheshti University of Medical Sciences” (IR.SBMU.MSP.REC.1397.552, Grant No. 14315).

Sample collection

In this case–control study, we collected serum and fresh biopsy tissues of patients suffering from gastric and colon cancer (27 gastric and 21 colon cancer tissues, serum and their adjacent normal tissues) who were hospitalized at Emam hossein hospital in Tehran between 2017 and 2018. All samples were stored in RNA later (Qiagen GmbH, Hilden, Germany) in − 20 °C. Furthermore, patient’s serum was collected and stored in − 70 °C until use. All personal information, including all patient’s clinic pathological data, were summarized in Table 1. The stage of the cancers was examined by expert pathologists. The samples of patients who had a history of chemotherapy were excluded from the study.

Table 1 The pathological information of gastric and colon samples

RNA extraction

To extract RNA, all tissues samples have been dissolved in RNX-plus solution by glass mortar, and proteins were removed from tissues and serum by RNX-plus solution (Cinnagen, Tehran, Iran) and chloroform. (After adding RNX-plus solution and chloroform and centrifuging all samples, RNA was available in upper solution.) Thereafter, RNA was precipitated with isopropanol, and washed with 70% ethanol. Finally, RNAs were dissolved in 50 μl of sterile water. The extracted RNAs were quantified by a Nanodrop spectrophotometry (Eppendorf, Humburg, Germany) at the wavelength of 260 nm. We used 1% agarose gel electrophoresis to confirm the purity of RNA.

Stem-loop real-time polymerase chain reaction (RT-PCR) for miRNA-9, -192 in tissue and serum samples

A same panel of two miRNAs (miR-9, miR-192) was employed to RT-PCR analysis in the tissue and serum samples along with their adjacent normal tissues. An equal volume of the eluted RNA and reverse transcriptase BioFACT were combined. Actually, to synthesize cDNA, we combined 8.5 μl of reverse transcriptase BioFACT (Daejeon, South Korea), 10 μl of RNA, 0.5 μl primer (10 pmol) of RTmicroRNA-9 (5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCATAC-3′), 0.5 μl primer (10 pmol) of RTmicroRNA-192 (5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGGCTGT-3′) and 0.5 μl (10 pmol) of the u6 reverse primer (5′-ATATGGAACGCTTCACGAATTTGC-3′). (choosing a stem-loop primer). All samples were incubated for 5 min at 95 °C and 40 min at 50 °C according to the manufacturer’s recommendations. In order to make suitable concentration, we diluted cDNAs two times with sterile water, and the final volume of sterile water and cDNA sample was 40 μl.

Quantitative RT-PCR (qRT-PCR)

Quantitative real-time PCR evaluated the accurate microRNA expression. Quantitative real-time PCR was performed by Rotor-gene 6000 (Corbett life sciences, Sydney, Australia) in 36-well Gene Discs, using a final volume of 20 μl. We have combined 10 μl of BIOFACT™ 2X real-time PCR master mix (for SYBR Green I; BIOFACT, South Korea), 1 μl (10 pmol) of forward primer, 1 μl of (10 pmol) reverse primer, 2 μl of 1/2 diluted cDNA and 6 μl of sterile water to evaluate the expression of miR-9-5p and miR-192-5p. U6 was employed to normalize the RNA input (normalization procedure was the same for both serum samples and tissues). To confirm our results, all experiments have been carried out in triplicate, simultaneously. (the same protocol was used to determine microRNAs expression levels both in serum and tissues). The list of primers used in this study are summarized in Table 2. Thermal cycling conditions was 95 °C for 10 min followed by 40 cycles of 95 °C for 20 s, 55 °C for 20 s, and 72 °C for 20 s. The melting curve analysis was performed with ramping 65–95 °C (raising by 0.5 °C each step). The values for the relative quantification were calculated based on 2−ΔΔct expression formula.

Table 2 Nucleotide sequences of primers used for real-time RT-PCR

Statistical analysis

To analysis the results of miRNAs expression, we used Graph-PadPrism software (version 5.1). Experimental data was expressed by mean ± standard deviation of three independent assays. The unpaired, two-tailed Student’s t test was used to analyze the statistical differences between groups using Graph-Pad Prism software. P < 0.05 was considered to indicate a statistically significant difference.

Results

Sample

As we could not extract the RNA of all tissues, some of the samples were excluded from further analyses. To evaluate the expression of miR-9-5p and miR-192-5p in gastric and colon cancer, we included 25 samples of gastric cancer (15 male, 10 female with the mean age of 68.3), adjacent normal gastric tissues (17 male, 8 female with mean age of 65.4), 18 colon cancer samples (5 male, 13 female; with the mean age of 62.4) and their adjacent normal ones (8 male, 10 female with mean age of 63). Moreover, the serum samples of each patient were collected. (27 gastric and 21 colon cancer) Of note, based on the clinical status, among gastric cancer tissues, 5 were considered as poorly differentiated, 9 as moderate differentiation and 11 of samples were well-differentiated adenocarcinoma. Likewise, 3 of the colon cancer samples were poorly differentiated, 5 displayed moderate differentiation and 10 were well-differentiated adenocarcinoma.

The expression level of miR-9-5p decreased in gastric cancer

To evaluate the expression level of miR-9-5p in both gastric and colon cancer, we performed real-time PCR analysis. As depicted in Fig. 1, our data showed that the expression level of miR-9-5p significantly decreased in gastric cancer tissues in comparison with the normal counterparts (P ≤ 0.05). This finding was further confirmed by the examination of the amount of miR-9-5p in the patient’s serum, which showed a remarkable reduction in miR-9-5p level (P ≤ 0.05) (Fig. 1). Unlike the gastric cancer, the expression level of miR-9-5p remained unchanged in both tissue and serum of colon cancer (Fig. 1).

Fig. 1
figure1

A a) The expression level of miR-9-5p significantly decreased in the tissues of gastric cancer (P ≤ 0.05) in comparison with the 25 normal tissues. b) There was also a reduction in the expression level of miR-9-5p in the serum of gastric cancer patients (P ≤ 0.05). Values are given as mean ± S.D. of three independent experiments. B a) Analyzing the expression level of miR-9-5p in colon cancer shown there was no noticeable difference between the expression level of miR-9-5p in the colon tissues samples b). Furthermore, our serum samples demonstrated that the expression level of this miRNA was remained unchanged. C a) The expression level of miR-192-5p indicated decrease in the gastric cancer tissues (P ≤ 0.05), b) but reduction in serum samples of patients, suffering from gastric cancer was not statistically significant. D a, b) The analysis of miR-192-5p expression shown that the level of miR-192-5p was not significantly reduced, neither in colon cancer tissues nor serum samples when compared with normal counterparts

miR-192-5p expression was reduced in gastric cancer tissues

Examination of miR-192-5p in gastric cancer showed that the expression level of this miRNA statistically decreased in cancerous tissues; however, we could not find any alteration in the expression level of miR-192-5p in the serum samples (Fig. 1). Moreover, we found that there was no significant difference between miR-192-5p expression levels in normal and colorectal cancer tissue (Fig. 1).

Discussion

Through binding to the specific sites, especially 3′UTR of mRNAs, microRNAs could robustly enhance or silence the expression level of wide range of genes, which are involved in different signaling pathways. This unique interactions categorized miRNAs into two groups, oncomiRs or tumor suppressors [22, 23]. Given to the well-established role of microRNAs in the pathogenesis of human cancers, these small non-coding RNAs are now considered as a promising biomarkers [24].

Previous studies has demonstrated that there is an association between the expression level of miR-9 and gastrointestinal cancers [20, 21, 25]. In the current study, we found that the expression level of miR-9-5p is significantly reduced both in the tissue and the serum of gastric cancer patients. This finding was in agreement with the recent studies suggesting that the expression level of miR-9 is downregulated in gastric cancer [26,27,28]. It seems, the evaluation of miR-9-5p in serum of patients, suffering from gastric cancer, can be considered as a biomarker. This result was similar to some studies which monitored different microRNAs in serum samples [29, 30]. The stimulatory of miR-9 in cancer progression is not only restricted to gastric cancer, since other studies also suggested that the expression of this miRNA could be altered in other human malignancies, including squamous cell carcinoma [31], breast cancer [32] and non-small-cell lung cancer [33]. Wan-Cheng Xiong et al. has demonstrated that the up-regulation of miR-9 in colon cancer cells is coupled with the suppression of tumor growth and cancer progression [23]. Moreover, in another study, it has been suggested that miR-9 could inhibit cell migration in colon cancer cells through down-regulation of TM4SF [34]. Of great interest, although the correlation between down-regulation of miR-9 and colon cancer has been examined in different studies, in many cases there are conflicting results. While a previous report indicated that miR-9 is down-regulated in colon cancer cells, other studies reported that miR-9 is over-expressed in colorectal cancer tissues [35, 36]. Given these, it was tempting to evaluate the expression level of miR-9 in colon cancer samples. Of particular interest, the results of our study delineated that there is no correlation between the expression level of miR-9 in, either in the tissue or in the serum of colon cancer.

In this study, we also evaluated the expression level of miR-192-5p. We found that the expression level of this miRNA remarkably decreased in gastric cancer tissues, proposing it as a promising screening biomarker. However, in colon cancer, the expression level of this miRNA remained unchanged. The previous results, showing a correlation between the expression of miR-192-5p and different cancers, displayed a controversially results in gastrointestinal cases. Chiang et al. has indicated that the expression of miR-192 decreased in colon cancer tissues [37]. Moreover, analyzing the amount of miR-192 in rat colon adenocarcinoma delineated the same results [38]. Yeunpo Chiang has also claimed a decrease in the expression level of miR-192 in gastric cell lines (MGC-803 cells, BGC-823 cells); however, they could not find any changes in the expression level of this miRNA in gastric cancer tissues [39]. Unlike these investigations, other studies has declared that the amount of miR-192 is increased in the plasma of gastric cancer patients [40, 41], human hepatocellular carcinoma [42] and non-small cell lung cancer [43]. The resulting data suggested that the expression of both miR-9-5p and miR-192-5p is down-regulated in gastric cancer, suggesting that these microRNAs could serve as a promising screening biomarker in gastric cancer, but not in colon cancer.

Limitation

The low number of sample was considered as the limitation of this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its additional files.

Abbreviations

miR-9-5p:

microRNA-9-5-p

miR-192-5p:

microRNA-192-5-p

References

  1. 1.

    Yasbolaghi Sharahi J, et al. In vitro antibacterial activity of curcumin-meropenem combination against extensively drug-resistant (XDR) bacteria isolated from burn wound infections. Avicenna J Phytomed. 2020;10(1):3–10.

  2. 2.

    Mahmoudi M, et al. Exosomes derived from mesenchymal stem cells improved function and survival of neutrophils from severe congenital neutropenia patients in vitro. Hum Immunol. 2019;80(12):990–8.

  3. 3.

    Faghihloo E, et al. Prevalence and characteristics of Epstein–Barr virus- associated gastric cancer in Iran. Arch Iran Med. 2014;17(11):767–70.

  4. 4.

    Mirzaei H, et al. Role of viruses in gastrointestinal cancer. J Cell Physiol. 2018;233(5):4000–14.

  5. 5.

    Pormohammad A, et al. Relationship of human herpes virus 6 and multiple sclerosis: a systematic review and meta-analysis. J Cell Physiol. 2018;233(4):2850–62.

  6. 6.

    Golrokh Mofrad M, et al. Prevalence of Epstein–Barr virus (EBV) in Iranian breast carcinoma patients. Asian Pac J Cancer Prev. 2020;21(1):133–7.

  7. 7.

    Lai EC. microRNAs: runts of the genome assert themselves. Curr Biol. 2003;13(23):R925–36.

  8. 8.

    Ambros V, et al. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol. 2003;13(10):807–18.

  9. 9.

    Zuo QF, et al. MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. Cell Death Dis. 2015;26(6):e2000.

  10. 10.

    Macchiaroli N, et al. Identification and expression profiling of microRNAs in hymenolepis. Int J Parasitol. 2019;49(3–4):211–23.

  11. 11.

    Khajehzadeh M, et al. Insight to the molecular mechanisms of the osmolyte effects on mycobacterium tuberculosis pyrazinamidase stability using experimental studies, molecular dynamics simulations, and free energy calculation. Int J Mycobacteriol. 2018;7(3):268–74.

  12. 12.

    Pourbagheri-Sigaroodi A, et al. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line. Eur J Pharmacol. 2019;846:49–62.

  13. 13.

    Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.

  14. 14.

    Li C, et al. Therapeutic microRNA strategies in human cancer. AAPS J. 2009;11(4):747.

  15. 15.

    Ma L, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247.

  16. 16.

    Faghihloo E et al (2016) Cdc6 expression is induced by HPV16 E6 and E7 oncogenes and represses E-cadherin expression. Cancer Gene Ther. https://doi.org/10.1038/cgt.2016.51.

  17. 17.

    Botla SK, et al. Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Res. 2016;76(14):4149–59.

  18. 18.

    Garofalo M, Di Leva G, Croce CM. MicroRNAs as anti-cancer therapy. Curr Pharm Des. 2014;20(33):5328–35.

  19. 19.

    Nilsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer. 2005;103(4):821–9.

  20. 20.

    Bandres E, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15(7):2281–90.

  21. 21.

    Ng EK, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81.

  22. 22.

    Takahashi R-U, et al. The role of extracellular vesicle microRNAs in cancer biology. Clin Chem Lab Med. 2017;55(5):648–56.

  23. 23.

    Xiong W-C, et al. microRNA-9 functions as a tumor suppressor in colorectal cancer by targeting CXCR4. Int J Clin Exp Pathol. 2018;11(2):526–36.

  24. 24.

    Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25–30.

  25. 25.

    Valladares-Ayerbes M, et al. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int J Oncol. 2011;39(5):1253–64.

  26. 26.

    Luo H, et al. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res. 2009;28(1):82.

  27. 27.

    Zheng L, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS ONE. 2013;8(1):e55719.

  28. 28.

    Ebrahimi-Askari R, Behmanesh M, Soleimani M. Analyses of methylation status of CpG islands in promoters of miR-9 genes family in human gastric adenocarcinoma. Mol Biol Res Commun. 2015;4(2):73.

  29. 29.

    Sierzega M, et al. Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331. Br J Cancer. 2017;117(2):266–73.

  30. 30.

    Ge Y. Serum microRNA expression profile as a biomarker for the diagnosis of pertussis. Mol Biol Rep. 2013;40(2):1325–32.

  31. 31.

    Sun L, et al. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients. Med Sci Monit Int Med J Exp Clin Res. 2016;22:289.

  32. 32.

    Baroni S, et al. Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis. 2016;7(7):e2312.

  33. 33.

    Sromek M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol. 2017;40(5):529–36.

  34. 34.

    Park YR, et al. MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int J Oncol. 2016;48(5):2135–43.

  35. 35.

    Snezhkina A, et al. Overexpression of microRNAs miR-9,-98, and-199 correlates with the downregulation of HK2 expression in colorectal cancer. Mol Biol. 2018;52(2):190–9.

  36. 36.

    Mohammadian F, et al. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. Artif cells Nanomed Biotechnol. 2017;45(6):1201–6.

  37. 37.

    Chiang Y, et al. microRNA-192,-194 and-215 are frequently downregulated in colorectal cancer. Exp Ther Med. 2012;3(3):560–6.

  38. 38.

    Davidson LA, et al. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis. 2009;30(12):2077–84.

  39. 39.

    Chiang Y, et al. Expression levels of microRNA-192 and-215 in gastric carcinoma. Pathol Oncol Res. 2012;18(3):585–91.

  40. 40.

    Chen Q, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014;31(4):1863–70.

  41. 41.

    Xu Y, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 2015;17(1):34–40.

  42. 42.

    Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, Wang Q, Zhao F, Li J, Yao M, Qin L. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget. 2016;7(3):2672.

  43. 43.

    Yunxia Z, Hongying D. Low expression of miR-192 in NSCLC and its tumor suppressor functions in metastasis via targeting ZEB2. Open Life Sci. 2016;11(1):293–7.

Download references

Acknowledgements

Not applicable.

Funding

The present study is financially supported by the Research Department of the School of Medicine Shahid Beheshti University of Medical Sciences; (IR.SBMU.MSP.REC.1397.552, Grant No. 14315). The role of funding included in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Affiliations

Authors

Contributions

EF and SHT designed the study and performed the molecular experiments. HG performed the statistical analyses. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ebrahim Faghihloo.

Ethics declarations

Ethics approval and consent to participate

This study has been conducted in Department of the School of Medicine Shahid Beheshti University of Medical. The written informed consent for participation was obtained from all patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tavakolian, S., Goudarzi, H. & Faghihloo, E. Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients. BMC Res Notes 13, 226 (2020). https://doi.org/10.1186/s13104-020-05071-9

Download citation

Keywords

  • miR-9-5p
  • miR-192-5p
  • Gastric cancer
  • Colon cancer
  • Real-time PCR